PercuSense To Present at the Chemical and Biological Defense Science & Technology Conference
November 8, 2024
PercuSense’s CEO, Brian Kannard, will be at the CBD S&T conference giving an oral presentation to unveil exciting new data from the ChemWatch system. For the first time, we will present in vivo data demonstrating the sensor’s ability to detect simulated warfare agents. This development marks a significant step forward in enhancing security and safety measures for our military and first responders. Join us at CBD S&T to hear our presentation titled, "Multi-Analyte Biosensing to Detect Indicators of Chemical Exposure (DICE)" to learn more about how our innovative technology is helping shape the future of chemical weapons defense.
PercuSense To Present at the 2024 Diabetes Technology Meeting in San Francisco
October 10, 2024
PercuSense will present at the 24th Annual Diabetes Technology Meeting in San Francisco, CA on October 15th-17th. PercuSense will be presenting a poster titled “Feasibility of Multi-Metabolic Continuous Monitoring: Atlas HealthTM, A Roadmap to Improving Metabolic Health” covering recent advancements in our dual analyte glucose and lactate sensor and the promise of lactate as a key metabolic analyte.
Groundbreaking First-in-Human Results from
Multi-Analyte Glucose and Lactate Sensor Published
August 19, 2024
PercuSense Inc. is thrilled to share the results of a groundbreaking first-in-human study, a clinical evaluation of the first-ever percutaneous multi-analyte CGM[+] system. PercuSense’s novel device combines glucose and lactate sensors on a single probe to provide simultaneous, continuous measurements of both analytes.
The results, detailed in the Journal of Diabetes Science and Technology article “Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans,” demonstrate the feasibility of a combined glucose and lactate sensor. Investigational device data was analyzed from 11 participants with Type 1 diabetes and compared with a commercially available Guardian 3 CGM. Participants underwent a meal-test followed by an exercise challenge on days 1 and 4 of wear. The performance was benchmarked against venous blood YSI glucose and lactate values.
The PercuSense glucose sensor performed comparably to a commercial glucose sensor, despite different calibration methods being utilized. PercuSense sensors were calibrated with the same universal calibration factor, while the commercial sensor was recalibrated at least twice a day. The lactate sensor tracked lactate changes with exercise, providing clinically relevant data. Importantly, there was no interference between the two sensing elements; the accuracy of one sensing element was not impacted when challenging the other through meals or exercise.
PercuSense Will Present at the 2024 ATTD Conference in Florence
February 2, 2024
PercuSense will exhibit and present at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy and online from March 6-9, 2024. Additionally, PercuSense’s clinical partners at the University of Melbourne will present results from first-in-human testing on PercuSense’s novel CGLM (glucose + lactate).
PercuSense Begins Next Phase in DICE Sensor Program
January 5, 2024
PercuSense has begun the fourth phase of collaboration with the Defense Threat Reduction Agency (DTRA) and Defense Innovation Unit (DIU) in work on a novel biosensor platform to provide for early detection and warning of potential exposure to chemical warfare agents. The DICE (Detecting Indicators of Chemical Exposure) program enters a new phase focused on continuing sensor detection capabilities and miniaturization and usability improvements to the wearable system.
PercuSense Completes First-in-Human Feasibility Testing on Novel Continuous Multi-Analyte Biosensor Platform
August 11, 2023
PercuSense has completed groundbreaking first-in-human feasibility testing on its continuous multi-analyte biosensor platform. The study was completed in collaboration with partners at the Diabetes Research Group at the University of Melbourne in Australia, The Helmsley Charitable Trust, and the U.S. Department of Defense. The study tested both a two-analyte continuous glucose and lactate sensor and a three-analyte sensor for detecting potential exposure to chemical warfare agents. The study established the feasibility of both novel sensor programs. Results will be presented at a later date.
PercuSense Continues Progress on Continuous Biosensor System for Early Detection of Toxic Chemical Exposure
January 25, 2023
PercuSense has continued its progress, in collaboration with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) and Defense Innovation Unit (DIU), on its body-worn biosensor designed to detect potential exposure to chemical warfare agents. The project leverages PercuSense’s novel biosensor platform, adapting it to monitor analytes relevant to chemical exposure. The program was recently highlighted in DIU’s annual report (page 34) in the link below.
PercuSense Announces Project with the University of Melbourne funded by The Helmsley Charitable Trust to Develop a Single Sensor Continuous Glucose and Ketone Monitor
November 2, 2020
By combining glucose and ketone on a single implantable sensor, PercuSense aims to reduce the risk of diabetic ketoacidosis, reducing the burden and ultimately increasing the treatment options for people with diabetes.
PercuSense Awarded $4.6M DIU/DTRA Contract to Develop Continuous Biosensor System for Early Detection of Toxic Chemical Exposure
May 28, 2020
PercuSense will leverage its continuous monitoring platform to create a field deployable on-body system designed to rapidly identifying chemical exposure and providing real time alerts to warfighters to drive threat reduction measures and treatment interventions.
Integration of Ketone Sensing into Closed Loop Systems: The Clinical Case
January 12, 2019
PercuSense’s founder, Rajiv Shah, contributed to a paper highlighting the clinical need and technical possibilities for combining a ketone sensor and glucose sensor into a single device. Such a device would provide the safety net that can prevent potentially serious incidents of diabetic ketoacidosis.
PercuSense Announced as a Finalist for MedTech Innovator Execution Award
September 18, 2018
PercuSense was named one of five finalists for the Execution Award, recognizing the potential of a promising entrepreneurial medical technology company.
PercuSense Selected to Participate in Medtech Innovator Startup Accelerator
June 13, 2018
PercuSense is honored to be selected as one of 25 early-stage companies participating in the Medtech Innovator Accelerator program. This sought-after program pairs companies with healthcare industry leaders who provide support and mentorship.